Goldman Sachs
INSY

Goldman Sachs’s Insys Therapeutics, Inc. INSY Stock Holding History

Goldman Sachs’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-25,000
Closed -$324K – 7293
2016
Q2 		$324K Sell
25,000
-24,700
-50% -$360K ﹤0.01% 5263
2016
Q1 		$795K Buy
+49,700
New +$944K ﹤0.01% 4288
2015
Q4 		– Sell
-800,000
Closed -$22.8M – 7490
2015
Q3 		$22.8M Buy
800,000
+290,000
+57% +$10.7M 0.01% 1622
2015
Q2 		$18.3M Buy
+510,000
New +$15.9M 0.01% 1857

Other funds holding INSY

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Goldman Sachs's INSY Position: Q2 2019 in Review

Goldman Sachs sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 157,592 shares — an estimated $728K sold.

Goldman Sachs first reported a position in INSY in Q4 2013 and held it in 22 quarters. The position peaked at $20.3M in Q3 2015. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

  • Goldman Sachs reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Goldman Sachs sold 157,592 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $728K.
  • Goldman Sachs first reported a position in Insys Therapeutics, Inc. in Q4 2013 and held it in 22 quarters.
  • Goldman Sachs's Insys Therapeutics, Inc. position peaked at $20.3M in Q3 2015.
  • 16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on Goldman Sachs's 13F filing for Q2 2019, filed 14 Aug 2019.